Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP decreased its stake in Inari Medical, Inc. (NASDAQ:NARI) by 12.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,208 shares of the company’s stock after selling 1,205 shares during the period. Bridgewater Associates LP’s holdings in Inari Medical were worth $338,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of NARI. GAMMA Investing LLC grew its position in shares of Inari Medical by 164.7% during the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after acquiring an additional 438 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Inari Medical by 7.7% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock worth $234,000 after purchasing an additional 348 shares during the last quarter. AlphaMark Advisors LLC acquired a new stake in shares of Inari Medical in the 2nd quarter worth $355,000. Nisa Investment Advisors LLC raised its holdings in Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in Inari Medical by 2.4% in the second quarter. Louisiana State Employees Retirement System now owns 26,000 shares of the company’s stock valued at $1,252,000 after purchasing an additional 600 shares during the period. 90.98% of the stock is owned by hedge funds and other institutional investors.

Inari Medical Stock Performance

NASDAQ NARI opened at $52.12 on Tuesday. The firm has a market capitalization of $3.05 billion, a PE ratio of -38.61 and a beta of 0.96. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $67.13. The company has a 50-day simple moving average of $46.48 and a 200-day simple moving average of $47.58.

Insider Buying and Selling

In other news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at approximately $22,265,500. This trade represents a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William Hoffman sold 60,000 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $51.16, for a total value of $3,069,600.00. Following the completion of the sale, the director now owns 501,233 shares of the company’s stock, valued at approximately $25,643,080.28. This trade represents a 10.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 186,000 shares of company stock valued at $8,990,990 in the last quarter. Company insiders own 10.60% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on NARI. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Piper Sandler boosted their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a report on Tuesday, October 29th. Truist Financial increased their target price on shares of Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a report on Tuesday, October 29th. Leerink Partnrs raised Inari Medical to a “hold” rating in a research note on Tuesday, September 3rd. Finally, Stifel Nicolaus assumed coverage on Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Inari Medical currently has a consensus rating of “Hold” and an average target price of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.